Boosting T cell energy to help immune cells fight cancer
Enhancing mitochondrial metabolism to improve anti-tumor CD8 immune response
Trying to increase the energy production inside T cells so CAR-T therapy works better for people with B‑cell leukemias and lymphomas.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11261039 on NIH RePORTER |
What this research studies
This work focuses on the mitochondria — the tiny energy factories inside CD8 T cells — and a protein called MCJ that lowers their energy output. Researchers found that reducing MCJ makes CD8 T cells more active and longer‑lived in lab and animal tests, and they plan to apply that insight to improve CD19 CAR‑T cells. The approach includes modifying T cell metabolism and testing effects on CAR‑T cell function, persistence, and cancer‑killing ability using lab models and patient‑derived samples. The team may also examine metabolic markers in human CAR‑T products to guide future clinical steps.
Who could benefit from this research
Good fit: People with relapsed or refractory B‑cell leukemias or lymphomas who are eligible for or considering CD19 CAR‑T therapy would be the most relevant candidates.
Not a fit: Patients with cancers not treated by CD19 CAR‑T (non‑B‑cell cancers) or those ineligible for CAR‑T therapy are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this could make CAR‑T treatments stronger and longer‑lasting, lowering the chance that leukemia or lymphoma comes back.
How similar studies have performed: Preclinical lab and animal studies show that lowering MCJ boosts CD8 T cell function, but translating metabolic tweaks into improved human CAR‑T outcomes is still novel and not yet proven in patients.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Rincon, Mercedes — University of Colorado Denver
- Study coordinator: Rincon, Mercedes
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.